



FOR IMMEDIATE RELEASE
May 14, 2008

IMRIS REPORTS CONTINUED GROWTH IN SALES AND ORDER BACKLOG

**Increasing order book demonstrates
strong momentum in market acceptance**

WINNIPEG, Manitoba, May 14, 2008 - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today reported its financial results for the first quarter ended March 31, 2008.

First Quarter Highlights:

- Revenues up 17% year-over-year due to an increase in *IMRISneuro* installations; increase was tempered by construction delays at customer site.
- Order backlog continues to show significant growth, increasing from \$31.7 million at December 31, 2007 to \$34.2 million at March 31, 2008 and to \$49.7 million as at the current date -- a 56% increase over the prior year.
- Added two new sales offices; a European office centered in Brussels, Belgium and an office in Sydney, Australia.

"We continue to execute against our business strategies," said David Graves, Chairman, President and Chief Executive Officer. "While deliveries were slightly below expectations due to construction delays at a customer site, our backlog of firm orders is up sharply to almost \$50 million. We believe this clearly demonstrates the market's confidence in our product and our strategic direction."

Mr. Graves continued, "We're also strengthening our position as a global company, with new offices in Europe and Australia to support our worldwide expansion strategy and to meet the expected demand for our products. We expect our order backlog to grow as we expand our addressable markets and secure more agreements with leading hospitals around the world."

Selected Financial Highlights
(in CDN dollars)
(Unaudited)

	First Quarter Ended March 31		%
	2008	2007	Change
Sales	4,158,136	3,566,293	17%
Gross profit	517,693	928,829	(44%)
Gross profit percentage	12.5%	26.0%	
Operating expenses	5,246,002	3,449,461	52%
Net loss	(4,404,512)	(2,512,857)	(75%)
Net loss per basic and diluted share	(0.16)	(0.17)	

First Quarter 2008 Results


Sales for the first quarter of 2008 were \$4.2 million, an increase of 17% over the first quarter of 2007. The year-over-year increase in revenues was directly attributable to an increase in *IMRISneuro* installations. The increase in sales was tempered by construction delays at one customer site that postponed the delivery of IMRIS' equipment to the next quarter.

Gross profit was \$0.5 million for the first quarter, a decrease of \$0.4 million from the \$0.9 million in the first quarter of 2007. As a percentage of sales, gross profit for the quarter declined from 26% in 2007 to 12.5% in the 2008 year. The lower margin percentage in the current quarter included a loss of \$0.2 million associated with the completion of previously announced luminary sites.

Operating expenses were \$5.2 million for the first quarter, an increase of \$1.8 million or 52% from the first quarter of 2007. This was due primarily to increased staffing as the Company continues to build organizational capacity across all functional areas to meet the anticipated growth in demand for IMRIS' products.

The net loss for the quarter was \$4.4 million or \$0.16 per share versus a loss of \$2.5 million or \$0.17 per share in the prior period. The increase in the loss was due to the higher operating expense levels to facilitate the Company's increased commercialization efforts and lower gross margins.

Outlook



During the first quarter of 2008 IMRIS booked one new order for an *IMRISneuro* system increasing the order backlog to \$34.2 million. Since quarter-end the Company has received three new orders to further increase the order backlog to \$49.7 million. This backlog is comprised of unrecognized revenue for three sites that are currently in progress as well as orders for an additional eight systems.

"IMRIS' outlook is better than ever as we build our backlog of orders and strengthen our position as the leader in surgical imaging systems," Graves said. "In addition to our expanding backlog, we continue to develop strong relationships with prospective customers around the world."

Mr. Graves added, "We take great pride in the feedback we have received on the positive impact that *IMRISneuro* has had in the market place. With our growing brand recognition, strong track record of successful implementations, and increasing market acceptance of our product, we feel confident about the company's future success."

The Company's full financial statements as well as management's discussion and analysis will be available at www.sedar.com and www.imris.com.

Conference Call

Management will host a conference call to discuss the results at **8:30 a.m. ET** (7:30 a.m. CT) on **Thursday, May 15, 2008**. Following management's presentation, there will be a question and answer session for analysts and institutional investors. To participate in the teleconference, please call **416-644-3420** or **1-800-732-0232**. To access the live audio webcast, please visit IMRIS' website at www.imris.com. A taped rebroadcast will be available to listeners following the call until midnight (ET) on May 22, 2008. To access the rebroadcast, please call 416-640-1917 or 1-877-289-8525 and enter passcode 21268872#. The webcast will also be archived on IMRIS' website.

About IMRIS

IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced surgical imaging solutions designed to measurably improve patient outcomes. The company's flagship product, *IMRISneuro*, utilizes patented technology that allows a high field MRI scanner to move in to the operating room on demand, providing imaging during the surgical procedure without compromising patient safety. This unique and innovative system has been validated by leading neurosurgeons around the world for use in world-class neuroscience centers.

For more information, visit www.imris.com

Forward-Looking Statements

This press release may contain or refer to forward-looking information based on current expectations. In some cases, forward-looking statements can be identified by terminology such as "may", "expect", "believe", "prospective", "continue" or the negative of these terms or other similar expressions concerning matters that are not historical facts. These statements should not be understood as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that actual results will be consistent with such statements. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. These forward-looking statements are made as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances.

For further information, please contact:

Ron Sabourin
Executive Vice President, Finance
and Chief Financial Officer
IMRIS Inc.
Tel: 204-480-7090
Email: rsabourin@imris.com

Susan McLeod
Manager, Marketing
Communications
IMRIS Inc.
Tel: 204-480-7094
Email: smcleod@imris.com